2013, Number 4
Med Int Mex 2013; 29 (4)
Inhibitors of Sodium-Glucose Transporter Type 2 in the Treatment of Diabetes Mellitus: Glycemic Control by Glucosuria
Galindo-Campos M, Carrillo-Ocampo L, Cortázar-Benítez F, Aisa-Álvarez A, Rodríguez-Weber F, Díaz-Greene E
PDF size: 183.59 Kb.
ABSTRACTType 2 diabetes mellitus is one of the public health problems with more relevance in the world because of its prevalence and its complications. There are many drugs that diminish glucose blood levels (principal aim in the treatment of diabetes mellitus), being the newest group the inhibitor of sodium-glucose transporter type 2 (SGLT2). The kidneys normally filter 180 g of glucose per day, this being reabsorbed by a family of transmembrane proteins called sodiumglucose transporters located in the proximal tubule. In 1970 it was discovered that the property of glucosuria of phlorizin is due to its inhibitory effect on SGLT 1 and 2. Currently dapagliflozin and other novel drugs are developed for selective inhibition of SGLT2 and apparently offer a therapeutic option for these patients. Current clinical evidence reveals the potential use of dapagliflozin as an auxiliary therapy in diabetes mellitus, as it has been shown to decrease levels of glycated hemoglobin with few adverse effects evidenced so far. Inhibitors sodium-glucose transporter is a drug adjuvant in the treatment of type 2 diabetes mellitus.